Company profile for Xcellon Biologics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Xcellon Biologics is a trusted CDMO dedicated to transforming scientific innovation into life-saving biologic therapies. We specialize in the development and manufacturing of complex biologics, offering end-to-end expertise from molecule to market with precision, speed, and scalability. Our capabilities include bioconjugate lead selection and development, bioprocess, analytical and formulation development, and machine learning...
Xcellon Biologics is a trusted CDMO dedicated to transforming scientific innovation into life-saving biologic therapies. We specialize in the development and manufacturing of complex biologics, offering end-to-end expertise from molecule to market with precision, speed, and scalability. Our capabilities include bioconjugate lead selection and development, bioprocess, analytical and formulation development, and machine learning–driven process optimization. With state-of-the-art facilities and decades of experience, Xcellon Biologics is redefining biologics development to deliver therapies with excellence and efficiency.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
12441 Parklawn Drive, Suite 2B North Bethesda, MD 20852
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/31/3178341/0/en/IntoCell-and-Xcellon-Biologics-Announce-MOU-to-Expand-Access-to-Next-Generation-ADC-Technologies.html

GLOBENEWSWIRE
31 Oct 2025

https://www.businesswire.com/news/home/20251022148688/en/Invenra-Inc.-and-Xcellon-Biologics-Announce-Collaboration-to-Advance-Bispecific-and-Trispecific-Antibody-Drug-Conjugate-ADC-Development

BUSINESSWIRE
22 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty